Retavase Reteplase recombinant - Rapid Reperfusion With Fixed Dosing For the Way You Treat AMI Today Retavase Flows With You™
Prompt Intervention | Prehospital Administration | In Vitro Data | Rapid Reperfusion | Safety Information | Convenient Fixed Dosing | Contact Information | Prescribing Information
Rapid Reperfusion
Significantly higher TIMI flow grade rates in RAPID II trial*
Significantly higher TIMI flow grade rates in RAPID II trial
Significantly higher TIMI flow grade rates in RAPID II trial
Adverse events observed in RAPID II trial*
Retavase - Adverse events observed in RAPID II trial
Percent of patients requiring transfusion (excluding those undergoing surgery) was 12.4% in the Retavase group, compared with 9.7% in the alteplase group (p=NS)1
Retavase - Adverse events observed in RAPID II trial
Of all hemorrhages, 4.4% and 3% were rated as severe or life-threatening in the Retavase and alteplase groups, respectively1
Retavase - Adverse events observed in RAPID II trial The incidence of stroke was also comparable with retavase and alteplase: total 1.8% vs 2.6%, hemorragic 1.2% vs 1.9%
*RAPID II trial, a multicenter, randomized study comparing the speed and completeness of coronary patency in patients treated with Retavase (n=157) or accelerated alteplase (n=146). This trial did not have sufficient power to detect differences in adverse events between the groups.
†Only the 90-minute assessment was mandatory, according to trial protocol.
Important Safety Information
Because thrombolytic therapy increases the risk of bleeding, including internal bleeding (such as intracranial, retroperitoneal, gastrointestinal, genitourinary, or respiratory), Retavase should be used only in those patients for whom its use is indicated in the prescribing information (see "Indications" in the prescribing information). In addition, thrombolytic therapy increases the absolute risk of stroke, including hemorrhagic stroke, in patients of advanced age. Cholesterol embolism has been reported rarely in patients treated with thrombolytic agents. Coronary thrombolysis may result in arrhythmias associated with reperfusion (see "Warnings" in the prescribing information).
Reference: 1. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996;94:891–898.
Please see full prescribing information.
    Marketed By  
   

© EKR Therapeutics, Inc. All rights reserved. January 2010.